Senior Program Manager

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified checked Jun 7, 2026

Salary

$164K-$205K From the posting source checked Jun 20, 2026

401(k) match

Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$61,842 U.S. median for this role

Projected growth (BLS Employment Projections)

+1.9% - Slower

198% above the BLS role benchmark for operations aggregate.

Matched to SOC 11-1021 - Operations aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function

Operations From the posting source checked Jun 20, 2026

Seniority

Senior From the posting source checked Jun 20, 2026

Schedule

Shift type

Not verified

Weekend work

Not verified

Company

Equity

Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Senior Program Manager Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: This is an exciting opportunity to advance first-in-Class RAS(ON) Inhibitors through clinical development. The ideal candidate is a strategic program management professional with deep experience leading cross-functional Companion Diagnostics (CDx) development activities supporting targeted oncology therapies. This individual will drive alignment across internal functions and external diagnostic partners to enable successful clinical development, regulatory execution, and commercialization readiness. The successful candidate will draw on their experience to: - Lead cross-functional Companion Diagnostics development programs supporting clinical-stage oncology assets from assay strategy through clinical and regulatory execution. - Work closely with CDx Leads and other clinical development team members to facilitate science-based CDx decision making and drive the execution of the CDx development strategy. - Develop and maintain integrated cross-functional program plans, timelines, milestones, dependencies, and critical path analyses across internal teams and external diagnostic partners. - Drive cross-functional alignment and coordinate CDx operational activities

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.